Trial · NCT05255900
Effects of Metyrapone in Patients With Hypercortisolism
NCT05255900, Completed, Istituto Auxologico Italiano
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effects of Metyrapone in Patients With Hypercortisolism. Trials, record NCT05255900. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05255900
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effects of Metyrapone in Patients With Hypercortisolism
- NCT number
- NCT05255900
- Status
- Completed
- Enrollment
- 20 participants, actual
- Lead sponsor
- Istituto Auxologico Italiano
- Conditions
- Hypercortisolism
- Interventions
- Metyrapone Capsules
- First posted
- 2022-02-25
- Last updated
- 2026-03-30
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Proportion of patients with a mean systolic BP reduction of ≥5 mm Hg | Baseline, 24 weeks | BP levels will be measured with arterial blood pressure monitoring (ABPM) |
| Secondary | Changes in glycometabolic control | 12 and 24 weeks | i) the proportion of patients without type 2 diabetes achieving normalization of FG (\<100 mg/dL) and/or the reduction of 2-hour glucose levels below 140 mg/dL after OGTT; ii) the proportion of patients with type 2 diabetes achieving HbA1c \<7% among those with baseline HbA1c ≥7%; |
| Secondary | Normalization of cortisol circadian rhythm | baseline, 12 weeks, 24 weeks. | The cortisol circadian rhythm will be assessed by salivary cortisol levels determination (at 8 AM, 12 AM, 4 PM, 8 PM and 11 PM). |
| Secondary | Changes of thrombotic risk parameters | Baseline, 12 and 24 weeks | The thrombotic risk profile will be evaluated by measuring C-Protein, S-Protein, coagulation factor VIII and anti-thrombin III levels |
| Secondary | Changes of lipid profile | Baseline, 12 and 24 weeks | The lipid profile modifications will be evaluated by measuring total cholesterol, low-density lipoprotein, high-density lipoprotein and triglycerides |
| Secondary | Changes of bone turnover markers | Baseline, 12 and 24 weeks | The bone turnover changes will be assessed by measuring calcium, phosphorous, osteocalcin (OC), carboxy-terminal cross-linked telopeptide of type I collagen (CTX) and 24-h urinary calcium/creatinine ratio |
| Secondary | Amelioration of psychological symptoms | Baseline, 12 and 24 weeks | Psychological symptoms wil be evaluated with Beck Depression Inventory-II (BDI-II), a 21-item self-administered inventory designed to measure the intensity of depressive symptoms (Beck, Steer, \& Brown, 1996). Scores ranging between 0 and 13 are indicative of minimal depression; scores that fall between 14 and 19 are considered to reflect a mild level of depression; scores of 20 to 28 are considered moderate; and a score ranging from 29 to 63 is labeled severe. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers39
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05255900
GET https://conductscience.org/api/trials/v1/NCT05255900/papers?page=2